HC Wainwright Reaffirms Buy Rating for Imunon (NASDAQ:IMNN)

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $12.00 price target on the stock.

Several other research firms also recently weighed in on IMNN. EF Hutton Acquisition Co. I raised shares of Imunon to a “strong-buy” rating in a research report on Monday, September 23rd. D. Boral Capital reiterated a “buy” rating and set a $29.00 price objective on shares of Imunon in a research note on Thursday.

Imunon Stock Performance

Shares of NASDAQ IMNN opened at $0.83 on Thursday. Imunon has a fifty-two week low of $0.48 and a fifty-two week high of $3.65. The company has a market cap of $12.04 million, a PE ratio of -0.44 and a beta of 2.12. The business has a 50-day simple moving average of $0.87 and a two-hundred day simple moving average of $1.07.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.